Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 11006-11012

  Jia, X F ^a   Li, J ^a   Zhao, H B ^a   Liu, J ^b   Liu, J J ^a  

^a First People's Hospital of Jining   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

EGFR; FISH; Metastasis; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; CHINA; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; GENETIC ASSOCIATION STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942093697     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.September.21.13     Document Type: Article

References (22)

1. Baselga J and Arteaga CL (2005). Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23: 2445-2459.
2. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, et al. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97: 643-655.
3. Dacic S, Flanagan M, Cieply K, Ramalingam S, et al. (2006). Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am. J. Clin. Pathol. 125: 860-865.
4. Han SW, Kim TY, Jeon YK, Hwang PG, et al. (2006). Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res. 12: 2538-2544.
5. Jeon YK, Sung SW, Chung JH, Park WS, et al. (2006). Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54: 387-398.
6. Jorissen RN, Walker F, Pouliot N, Garrett TP, et al. (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284: 31-53.
7. Khambata-Ford S, Harbison CT, Hart LL, Awad M, et al. (2010). Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28: 918-927.
8. Lee HJ, Xu X, Choe G, Chung DH, et al. (2010). Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 68: 375-382.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129-2139.
10. Paez JG, Jӓnne PA, Lee JC, Tracy S, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
11. Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
12. Pinter F, Papay J, Almasi A, Sapi Z, et al. (2008). Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J. Mol. Diagn. 10: 160-168.
13. Pirker R, Pereira JR, von Pawel J, Krzakowski M, et al. (2012). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13: 33-42.
14. Rivera MP (2004). Multimodality therapy in the treatment of lung cancer. Semin. Respir. Crit. Care Med. 25: 3-10.
15. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, et al. (2007). The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75: 770-787.
16. Stinchcombe TE and Socinski MA (2010). Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy. Nat. Rev. Clin. Oncol. 7: 426-428.
17. Sun G, Liu B, He J, Zhao X, et al. (2015) Expression of EGFR Is Closely Related to Reduced 3-Year Survival Rate in Chinese Female NSCLC. Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res. 21: 2225-2231.
18. Tamura K, Okamoto I, Kashii T, Negoro S, et al. (2008). Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 98: 907-914.
19. Tang X, Shigematsu H, Bekele BN, Roth JA, et al. (2005). EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 65: 7568-7572.
20. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, et al. (2005). Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353: 133-144.
21. Xia LP, Qiu HJ, Chen XX, Hu PL, et al. (2011). Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. Med. Oncol. 28: S570-576.
22. Zhang ZH, Yu M, Ni CC and Lu YJ (2010). The expression of EGFR in non-small cell lung cancer and its clinical significance. J. Clin. Pulm. Med. 15: 1079-1081.